Skip to contentG
Grace Therapeutics, Inc.
G
GRCEGrace Therapeutics, Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$2.39M-$2.39MN/M vs Q3 2023 EPS Diluted-$0.21-$0.21N/M vs Q3 2023 Operating Income-$3,043,000N/M Operating Cash Flowderived-$1,892,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 12, 2024 · 43 d after period end